Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Lymphoma

Free Subscription Articles published in Br J Haematol Retrieve available abstracts of 220 articles: HTML format

Single Articles

October 2025
1. MUNZ N, Arribas AJ, Bordone Pittau R, Simonetta F, et al
   Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma.
   Br J Haematol. 2025 Oct 7. doi: 10.1111/bjh.70185.
   PubMed    
   
   
   
2. HU X, Li L, Nkwocha J, Vasiyani H, et al
   Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma lines.
   Br J Haematol. 2025 Oct 5. doi: 10.1111/bjh.70188.
   PubMed     Abstract available
   
   
   
3. CHIRIAC R, Baseggio L
   Reed-Sternberg-like cells in central nervous system relapse of diffuse large B-cell lymphoma.
   Br J Haematol. 2025 Oct 2. doi: 10.1111/bjh.70174.
   PubMed    
   
   
   
4. SUH M, Hyung J, Park CS, Go H, et al
   Prognostic significance of pretransplant (18)F-FDG PET/CT metrics in relapsed/refractory diffuse large B-cell lymphoma with partial response to salvage chemotherapy prior to autologous stem cell transplantation.
   Br J Haematol. 2025 Oct 1. doi: 10.1111/bjh.70186.
   PubMed     Abstract available
   
   
   
5. SHENG X, Wang D, Li S, Li B, et al
   Targeting small ubiquitin-related modifier-specific protease 2 attenuates tumour progression and orchestrates the tumour immune microenvironment in diffuse large B-cell lymphoma.
   Br J Haematol. 2025 Oct 1. doi: 10.1111/bjh.70187.
   PubMed     Abstract available
   
   
   
6. LYNCH RC, Cassaday RD, Smith SD, Cowan AJ, et al
   Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.
   Br J Haematol. 2025;207:1599-1603.
   PubMed     Abstract available
   
   
   
7. WU R, Li Y, Zhang D, Liu T, et al
   Population pharmacokinetics of high-dose methotrexate and 7-hydroxy methotrexate in Chinese adults with primary central nervous system lymphoma.
   Br J Haematol. 2025;207:1622-1627.
   PubMed    
   
   
   
8. MARTINEZ ALCALA R, Lei Y, Visser L, Diepstra A, et al
   Programmed cell death-1 inhibition activates CD4 T cells in a novel in vitro model of Hodgkin lymphoma.
   Br J Haematol. 2025;207:1643-1647.
   PubMed    
   
   
   
9. TRIANTAFILO N, Chowdhury A, Thiruvengadam S, Herrera AF, et al
   Real-world experience with CAR-T therapy in relapsed and refractory follicular lymphoma.
   Br J Haematol. 2025;207:1668-1672.
   PubMed    
   
   
   September 2025
10. KALASHNIKOV I, Reunamo T, Tanskanen T, Viisanen L, et al
    Transformation and causes of death in follicular lymphoma: A Finnish nationwide population-based study.
    Br J Haematol. 2025 Sep 25. doi: 10.1111/bjh.70181.
    PubMed     Abstract available
    
    
    
11. OLSZEWSKI AJ, Treaba DO, Winter A, Donnelly S, et al
    Loncastuximab tesirine elicits complete responses in secondary central nervous system lymphoma.
    Br J Haematol. 2025 Sep 21. doi: 10.1111/bjh.70178.
    PubMed    
    
    
    
12. PATZKE S, Cascione L, Melhus KB, Munz N, et al
    Comprehensive analysis of (177)Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes.
    Br J Haematol. 2025 Sep 18. doi: 10.1111/bjh.70143.
    PubMed     Abstract available
    
    
    
13. LI Y, Jin L, Liu W, Liu Y, et al
    Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.
    Br J Haematol. 2025 Sep 16. doi: 10.1111/bjh.70097.
    PubMed     Abstract available
    
    
    
14. BAHABRI AS, Lau C, Kim VHD, Alexander S, et al
    Incidence and impact of prior history of serious infection in paediatric lymphoma: A population-based study.
    Br J Haematol. 2025 Sep 15. doi: 10.1111/bjh.70157.
    PubMed     Abstract available
    
    
    
15. KUHNL A, Bouziana S, Barrington SF, Galani S, et al
    MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy.
    Br J Haematol. 2025 Sep 11. doi: 10.1111/bjh.70137.
    PubMed    
    
    
    
16. VODICKA P, Hamova I, Velasova A, Kupcova K, et al
    Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.
    Br J Haematol. 2025 Sep 7. doi: 10.1111/bjh.70128.
    PubMed     Abstract available
    
    
    
17. CHAGANTI S, Dulobdas V, Wilson MR, Tucker D, et al
    Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper.
    Br J Haematol. 2025 Sep 5. doi: 10.1111/bjh.70018.
    PubMed    
    
    
    
18. SONG Y, Zou D, Yang H, Wu J, et al
    Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study.
    Br J Haematol. 2025 Sep 1. doi: 10.1111/bjh.20122.
    PubMed     Abstract available
    
    
    
19. NORDKIN M, Fadaos N, Leiba R, Sharon-Horesh N, et al
    Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigm.
    Br J Haematol. 2025;207:1104-1107.
    PubMed    
    
    
    
20. BARONE A, De Philippis C, Stella F, Dodero A, et al
    Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes.
    Br J Haematol. 2025;207:956-964.
    PubMed     Abstract available
    
    
    
21. JO T, Arai Y, Shimizu T, Kitawaki T, et al
    Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post-CAR-T-cell therapy.
    Br J Haematol. 2025;207:1002-1010.
    PubMed     Abstract available
    
    
    
22. JOHNSTONE P, Higgins M, Prince HM, Lade S, et al
    Large-cell transformation of mycosis fungoides: Patterns of care and patient outcomes.
    Br J Haematol. 2025;207:824-833.
    PubMed     Abstract available
    
    
    August 2025
23. MARIOTTI J, Pinton C, Giordano L, Taurino D, et al
    Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis.
    Br J Haematol. 2025 Aug 31. doi: 10.1111/bjh.70091.
    PubMed     Abstract available
    
    
    
24. KLEINSTERN G, Robinson DP, Abu Seir R, Perlman R, et al
    European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs.
    Br J Haematol. 2025 Aug 31. doi: 10.1111/bjh.70125.
    PubMed     Abstract available
    
    
    
25. LUMINARI S, Barbieri E, Nizzoli ME
    Towards a chemo-free approach for follicular lymphoma.
    Br J Haematol. 2025 Aug 30. doi: 10.1111/bjh.70126.
    PubMed     Abstract available
    
    
    
26. YU F, Yu X, Hu X, Jiang E, et al
    Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025 Aug 26. doi: 10.1111/bjh.70102.
    PubMed     Abstract available
    
    
    
27. KOCA O, Eskazan AE
    Refining the risk stratification in advanced-stage classical Hodgkin lymphoma: A critical analysis of clinical prediction models.
    Br J Haematol. 2025 Aug 22. doi: 10.1111/bjh.70115.
    PubMed     Abstract available
    
    
    
28. TE VRUGT M, Newman H, Teachey DT, Burkhardt B, et al
    T-cell lymphoblastic lymphoma in children, adolescents and young adults.
    Br J Haematol. 2025 Aug 13. doi: 10.1111/bjh.70053.
    PubMed     Abstract available
    
    
    
29. MORIMOTO S, Jo T, Kitawaki T, Sakamoto T, et al
    Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma.
    Br J Haematol. 2025 Aug 11. doi: 10.1111/bjh.70090.
    PubMed     Abstract available
    
    
    
30. TRAB T, Ranadottir T, Chanchiri I, Ludvigsen Al-Mashhadi A, et al
    Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population-based study.
    Br J Haematol. 2025 Aug 8. doi: 10.1111/bjh.70082.
    PubMed     Abstract available
    
    
    July 2025
31. CARPIO C, de la Cruz-Vicente F, Garcia-Sanz R, Zeberio I, et al
    A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial.
    Br J Haematol. 2025 Jul 25. doi: 10.1111/bjh.70028.
    PubMed     Abstract available
    
    
    
32. HOSSAIN NM, Ahn KW, Patel J, Lian Q, et al
    Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS.
    Br J Haematol. 2025 Jul 22. doi: 10.1111/bjh.70020.
    PubMed     Abstract available
    
    
    
33. REGAZZO G, Vari G, Marchesi F, Diaz Mendez AB, et al
    A predictive serum miRNA signature impacts diffuse large B-cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis.
    Br J Haematol. 2025 Jul 20. doi: 10.1111/bjh.70017.
    PubMed     Abstract available
    
    
    
34. KHAVANDI MM, Strati P, Habibollahi P
    Minimally invasive percutaneous lymphangiography and embolisation for spontaneous chyle leaks in patients with lymphoma.
    Br J Haematol. 2025 Jul 15. doi: 10.1111/bjh.70007.
    PubMed    
    
    
    
35. SEVERINSEN FT, Simonsen MR, Futtrup Maksten E, Jakobsen LH, et al
    Late infections after high-dose therapy and autologous stem cell transplantation for lymphoma: A Danish population-based study.
    Br J Haematol. 2025 Jul 13. doi: 10.1111/bjh.20262.
    PubMed     Abstract available
    
    
    
36. PARTANEN A, Ronka A, Anttalainen A, Ukkola-Vuoti L, et al
    Nodal peripheral T-cell lymphoma in Finland between 2007 and 2019: Incidence, late morbidity and survival.
    Br J Haematol. 2025 Jul 10. doi: 10.1111/bjh.20253.
    PubMed     Abstract available
    
    
    
37. MOIOLI A, Visco C
    We are on the right track for mantle cell lymphoma.
    Br J Haematol. 2025 Jul 6. doi: 10.1111/bjh.20259.
    PubMed     Abstract available
    
    
    
38. ALZAHRANI M, Gerrie AS, Sehn LH, Scott DW, et al
    Therapeutic advances and gradual improvement in overall survival in mantle cell lymphoma over four decades.
    Br J Haematol. 2025 Jul 2. doi: 10.1111/bjh.20239.
    PubMed    
    
    
    
39. GASCON P, Frankel D, Fritz S, Comet A, et al
    Vitrectomy as a rapid diagnostic tool for lymphoma: Cytology and flow cytometry approach.
    Br J Haematol. 2025 Jul 1. doi: 10.1111/bjh.20250.
    PubMed    
    
    
    
40. CASSANELLO G, Luttwak E, Brown S, Devlin SM, et al
    Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.
    Br J Haematol. 2025 Jul 1. doi: 10.1111/bjh.20234.
    PubMed     Abstract available
    
    
    
41. HANAJIRI R, Wakabayashi H, Ishigiwa K, Ohara F, et al
    Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion.
    Br J Haematol. 2025;207:180-188.
    PubMed     Abstract available
    
    
    June 2025
42. SHARP J, Zhao Q, Voorhees TJ, Bond DA, et al
    Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma.
    Br J Haematol. 2025 Jun 30. doi: 10.1111/bjh.20240.
    PubMed     Abstract available
    
    
    
43. MOLINA F, Sureda A, Mussetti A
    Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed/refractory large B-cell lymphoma, including in the CAR T-cell era.
    Br J Haematol. 2025 Jun 25. doi: 10.1111/bjh.20217.
    PubMed    
    
    
    
44. WEI C, Zhang Y, Zhao D, Zhang W, et al
    Germline defects of familial haemophagocytic lymphohistiocytosis-Related genes may represent a predisposing factor for mature T- and natural killer-cell lymphoma.
    Br J Haematol. 2025 Jun 23. doi: 10.1111/bjh.20231.
    PubMed     Abstract available
    
    
    
45. UPPAL M, Joseph A, Drill E, Hamlin P, et al
    Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma.
    Br J Haematol. 2025 Jun 23. doi: 10.1111/bjh.20202.
    PubMed    
    
    
    
46. 
    Correction to "Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma".
    Br J Haematol. 2025 Jun 19. doi: 10.1111/bjh.20237.
    PubMed     Abstract available
    
    
    
47. CHUNG K, Ng LS, Yee CI, Bansal R, et al
    Impact of granulocyte colony-stimulating factor on safety of chimeric antigen receptor-T-cell therapy in non-Hodgkin lymphoma.
    Br J Haematol. 2025 Jun 17. doi: 10.1111/bjh.20207.
    PubMed    
    
    
    
48. YILMAZ U, Terzi Demirsoy E, Keklik Karadag F, Hatipoglu U, et al
    Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B-cell lymphoma cohort.
    Br J Haematol. 2025 Jun 16. doi: 10.1111/bjh.20111.
    PubMed     Abstract available
    
    
    
49. HUIYING Z, Congwei J, Yue C, Lu Z, et al
    Arborising telangiectasia in intravascular large B-cell lymphoma.
    Br J Haematol. 2025 Jun 12. doi: 10.1111/bjh.20172.
    PubMed    
    
    
    
50. CHIRIAC R, Baseggio L
    Chronic lymphocytic leukaemia extravaganza: Vacuolated lymphoma cells.
    Br J Haematol. 2025 Jun 11. doi: 10.1111/bjh.20162.
    PubMed    
    
    
    
51. NOVO M, Frascione PMM, Castellino A, Marcheselli L, et al
    Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL).
    Br J Haematol. 2025 Jun 10. doi: 10.1111/bjh.20204.
    PubMed     Abstract available
    
    
    
52. DITTUS C, Weinstock MJ, Barnes J, Sandoval-Sus J, et al
    Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2025 Jun 3. doi: 10.1111/bjh.20177.
    PubMed    
    
    
    
53. SORIAL MN, Han JX, Koh MJ, Boussi L, et al
    Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.
    Br J Haematol. 2025;206:1664-1677.
    PubMed     Abstract available
    
    
    May 2025
54. GLEESON M, Gonzalez Arias C, Cunningham D, Peckitt C, et al
    The role of PET/CT in peripheral T-cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO-T trial.
    Br J Haematol. 2025 May 26. doi: 10.1111/bjh.20160.
    PubMed     Abstract available
    
    
    
55. HARLAY V, Gallardo C, Beaufils N, Astier A, et al
    Evaluation of MYD88 p.L265P detection by digital droplet polymerase chain reaction in cerebrospinal fluid for integrated diagnosis of primary large B-cell lymphoma of the central nervous system.
    Br J Haematol. 2025 May 25. doi: 10.1111/bjh.20167.
    PubMed    
    
    
    
56. SRINIVASAN S, Narayan A, Dhamne C, Chichra A, et al
    Combination of fixed low-dose nivolumab and bendamustine in children with high-risk relapsed/refractory classical Hodgkin lymphoma.
    Br J Haematol. 2025 May 20. doi: 10.1111/bjh.20148.
    PubMed     Abstract available
    
    
    
57. CHAGANTI S, Fox CP, Maybury BD, Burton C, et al
    Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline.
    Br J Haematol. 2025 May 19. doi: 10.1111/bjh.20129.
    PubMed     Abstract available
    
    
    
58. HAUJIR A, Tostesen M, El-Galaly TC, Larsen TS, et al
    Effectiveness of rituximab and biosimilar rituximab in untreated diffuse large B-cell lymphoma, a Danish population-based analysis.
    Br J Haematol. 2025 May 15. doi: 10.1111/bjh.20155.
    PubMed    
    
    
    
59. HAFI M, Iyengar S, Wotherspoon A, Cunningham D, et al
    Involvement of the gastrointestinal tract by mantle cell lymphoma.
    Br J Haematol. 2025 May 15. doi: 10.1111/bjh.20048.
    PubMed    
    
    
    
60. LOWE EJ, Woessmann W
    Anaplastic large cell lymphoma in children and adolescents.
    Br J Haematol. 2025 May 12. doi: 10.1111/bjh.20154.
    PubMed     Abstract available
    
    
    
61. TANG C, Downie C, Sagoo MS, Pringle E, et al
    An international real-world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaborators.
    Br J Haematol. 2025 May 6. doi: 10.1111/bjh.20115.
    PubMed     Abstract available
    
    
    
62. AOKI T, Salib M, Suleman A, Ghanem N, et al
    Distinct characteristics and social determinants in adult T-cell leukaemia/lymphoma patients at a tertiary cancer centre in Canada.
    Br J Haematol. 2025 May 6. doi: 10.1111/bjh.20132.
    PubMed     Abstract available
    
    
    
63. HARROP S, Casan J, Rose H, Sullivan M, et al
    Heterozygous germline TET2 loss-of-function variants associated with an ALPS-like phenotype.
    Br J Haematol. 2025;206:1330-1334.
    PubMed     Abstract available
    
    
    April 2025
64. VALLET N, Picou F, Arbion F, Doyen H, et al
    Aberrant antioxidant responses in B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2025 Apr 30. doi: 10.1111/bjh.20108.
    PubMed    
    
    
    
65. HERBAUX C, Bachy E, Bouabdallah R, Guidez S, et al
    Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.
    Br J Haematol. 2025 Apr 26. doi: 10.1111/bjh.20109.
    PubMed     Abstract available
    
    
    
66. HARRYSSON S, Eloranta S, Antonilli S, Runason Simonsen M, et al
    Temporal trends in relative survival of diffuse large B-cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies.
    Br J Haematol. 2025 Apr 23. doi: 10.1111/bjh.20104.
    PubMed    
    
    
    
67. SUZUKI T, Fujii K, Matsunaga N, Sasaki H, et al
    Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2025 Apr 22. doi: 10.1111/bjh.20099.
    PubMed     Abstract available
    
    
    
68. NIRMAL G, Thankamony P, Nair RA, Nair M, et al
    Resource-adapted strategies in the management of paediatric Burkitt lymphoma in low- and middle-income country setting and outcomes: An Indian centre experience.
    Br J Haematol. 2025 Apr 22. doi: 10.1111/bjh.20093.
    PubMed     Abstract available
    
    
    
69. CERIANI L, Milan L, Chauvie S, Zucca E, et al
    Understandings 18 FDG PET radiomics and its application to lymphoma.
    Br J Haematol. 2025 Apr 15. doi: 10.1111/bjh.20074.
    PubMed     Abstract available
    
    
    
70. MIAO Y, Qian S, Gao L, Zhou Z, et al
    Prognostic impacts of RHOA G17V mutation in cell-free DNA assessed by droplet digital polymerase chain reaction in patients with angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2025 Apr 7. doi: 10.1111/bjh.20071.
    PubMed    
    
    
    
71. LOPEDOTE P, Shouse G, Puverel S, Muir A, et al
    A chemotherapy-free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma.
    Br J Haematol. 2025 Apr 2. doi: 10.1111/bjh.20041.
    PubMed    
    
    
    
72. GIORDANO C, Picardi M, Pugliese N, Vincenzi A, et al
    Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic Hodgkin lymphoma in patients aged
    Br J Haematol. 2025 Apr 2. doi: 10.1111/bjh.20053.
    PubMed    
    
    
    March 2025
73. PIEROG O, Craig T, Jennings J, Borowitz MJ, et al
    The real-world application of T-cell receptor constant beta-1 chain antibody assay in cutaneous T-cell lymphoma.
    Br J Haematol. 2025 Mar 24. doi: 10.1111/bjh.20060.
    PubMed     Abstract available
    
    
    
74. BRAY JS, Thomas GR, Smith VM, Wright A, et al
    In vitro comparison of CD20xCD3 biosimilar antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20.
    Br J Haematol. 2025 Mar 3. doi: 10.1111/bjh.20033.
    PubMed     Abstract available
    
    
    
75. MOZAS P, Ould Ammar R, Chartier L, Nastoupil L, et al
    A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis.
    Br J Haematol. 2025 Mar 3. doi: 10.1111/bjh.20038.
    PubMed     Abstract available
    
    
    
76. MALLET V, Torres HA
    Hepatitis E virus infection after CAR T-cell treatment: An important complication in patients already facing significant health challenges.
    Br J Haematol. 2025;206:1020-1021.
    PubMed     Abstract available
    
    
    February 2025
77. MATO S, Carita L, Colmenero A, Andres M, et al
    Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents.
    Br J Haematol. 2025 Feb 26. doi: 10.1111/bjh.20012.
    PubMed     Abstract available
    
    
    
78. ZHAO J, Liu TF, Wu KF, Yang LC, et al
    Clinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups.
    Br J Haematol. 2025 Feb 17. doi: 10.1111/bjh.20011.
    PubMed     Abstract available
    
    
    
79. WANG G, Wang F
    Immunoglobulin inclusions were released from lymphoma cells and deposited as cryoglobulin crystals in a peripheral blood film.
    Br J Haematol. 2025 Feb 17. doi: 10.1111/bjh.20005.
    PubMed    
    
    
    
80. KOH YK, Yoon SH, Kang SH, Koh KN, et al
    Immunosuppressive therapy as first-line and relapse treatment in paediatric subcutaneous panniculitis-like T-cell lymphoma.
    Br J Haematol. 2025 Feb 16. doi: 10.1111/bjh.20014.
    PubMed    
    
    
    
81. IVANOVA VS, Menter T, Cui N, Leary P, et al
    Distinct subtypes of post-transplant lymphoproliferative disorders: CHIP-like mutations in early lesions and substantial mutational differences between EBV-positive and EBV-negative diffuse large B-cell lymphomas.
    Br J Haematol. 2025;206:484-504.
    PubMed     Abstract available
    
    
    
82. EL-GALALY TC, Roug AS, Kristensen DT
    A successful clinical trial ecosystem offers equal opportunities for all citizens.
    Br J Haematol. 2025;206:788-789.
    PubMed     Abstract available
    
    
    January 2025
83. DRAGOI D, Cusworth S, Oldham L, Sanderson R, et al
    CAR T access and outcomes in large B-cell lymphoma according to ethnicity and socioeconomic deprivation in the UK.
    Br J Haematol. 2025 Jan 16. doi: 10.1111/bjh.19997.
    PubMed     Abstract available
    
    
    
84. SHIWAKU T, Tamefusa K, Ishida H, Fujiwara K, et al
    Paediatric anaplastic large-cell lymphoma with cardiac tamponade.
    Br J Haematol. 2025 Jan 12. doi: 10.1111/bjh.19980.
    PubMed    
    
    
    
85. CHIRIAC R
    Concomitant HIV-associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation.
    Br J Haematol. 2025 Jan 12. doi: 10.1111/bjh.19971.
    PubMed    
    
    
    
86. MUNAKATA W, Kumode T, Goto H, Fukuhara N, et al
    A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study.
    Br J Haematol. 2025 Jan 8. doi: 10.1111/bjh.19994.
    PubMed     Abstract available
    
    
    
87. LEW-DERIVRY L, Chevillon F, Brice P, Bigenwald C, et al
    Should adolescents and young adults with Hodgkin lymphoma be treated as children or adults?
    Br J Haematol. 2025 Jan 5. doi: 10.1111/bjh.19985.
    PubMed     Abstract available
    
    
    
88. LIN J, Mu Y, Liu L, Meng Y, et al
    Machine learning based on multiplatform tests assists in subtype classification of mature B-cell neoplasms.
    Br J Haematol. 2025;206:224-234.
    PubMed     Abstract available
    
    
    
89. CAPES A, Morin A, Banet A, Suner L, et al
    Severe cytopenia after chimeric antigen receptor-T cell driven by large granular lymphocytes and responsive to steroids.
    Br J Haematol. 2025;206:180-185.
    PubMed     Abstract available
    
    
    December 2024
90. STELLA F, Chiappella A, Magni M, Bonifazi F, et al
    Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study.
    Br J Haematol. 2024 Dec 22. doi: 10.1111/bjh.19961.
    PubMed     Abstract available
    
    
    
91. ZAMMAR G, Cheah CY
    Treating asymptomatic follicular lymphoma: What is the score?
    Br J Haematol. 2024 Dec 18. doi: 10.1111/bjh.19949.
    PubMed     Abstract available
    
    
    
92. DE LA IGLESIA-SAN SEBASTIAN I, Lopez-Esteban M, Bastos-Oreiro M, Fernandez de Cordoba-Onate S, et al
    Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy.
    Br J Haematol. 2024 Dec 12. doi: 10.1111/bjh.19916.
    PubMed     Abstract available
    
    
    
93. STRATI P, Agajanian R, Lossos IS, Coleman M, et al
    Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).
    Br J Haematol. 2024 Dec 12. doi: 10.1111/bjh.19951.
    PubMed     Abstract available
    
    
    
94. CHOY J, Lewis KL
    In the SARS-CoV-2 era, do we need to be afraid of obinutuzumab?
    Br J Haematol. 2024;205:2113-2115.
    PubMed     Abstract available
    
    
    
95. CALIMERI T, Ferreri AJM
    CNS prophylaxis in large B-cell lymphomas: A balance with three pans.
    Br J Haematol. 2024;205:2116-2118.
    PubMed     Abstract available
    
    
    November 2024
96. MARZOLINI MAV, Qian W, Clifton-Hadley L, Patrick P, et al
    Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting.
    Br J Haematol. 2024 Nov 27. doi: 10.1111/bjh.19918.
    PubMed     Abstract available
    
    
    
97. JONES DA, Spencer K, Ramroth J, Probert J, et al
    Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England.
    Br J Haematol. 2024 Nov 27. doi: 10.1111/bjh.19907.
    PubMed     Abstract available
    
    
    
98. SCHENA A, Quaglia FM, Parisi A, Ferrarini I, et al
    Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma.
    Br J Haematol. 2024 Nov 13. doi: 10.1111/bjh.19883.
    PubMed    
    
    
    
99. SCHWARZ M, Mozayani B, Trauner M, Stattermayer AF, et al
    Chronic hepatitis E in a patient after chimeric antigen receptor-T-cell treatment for diffuse large B-cell lymphoma and rapid progression towards decompensated liver cirrhosis.
    Br J Haematol. 2024 Nov 7. doi: 10.1111/bjh.19892.
    PubMed    
    
    
    
100. KIM JL, Villa D, Tonseth RP, Gerrie AS, et al
     Long-term follow-up of bulky classic Hodgkin lymphoma managed with ABVD and PET-guided RT demonstrates excellent outcomes in PET-negative cases.
     Br J Haematol. 2024 Nov 7. doi: 10.1111/bjh.19859.
     PubMed     Abstract available
     
     
     
101. BARRETT A, Shah N, Chadwick A, Burns D, et al
     Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper.
     Br J Haematol. 2024 Nov 6. doi: 10.1111/bjh.19840.
     PubMed     Abstract available
     
     
     
102. LI JR, Shaw VR, Parthasarathy A, Li Y, et al
     Prognostic stratification in DLBCL patients with aberrant MYC gene.
     Br J Haematol. 2024;205:1782-1793.
     PubMed     Abstract available
     
     
     
103. CAMPBELL BA, Dobos G, Haider Z, Bagot M, et al
     Improving disease-specific survival for patients with Sezary syndrome in the modern era of systemic therapies.
     Br J Haematol. 2024;205:1825-1829.
     PubMed     Abstract available
     
     
     October 2024
104. KARSTEN IE, Shumilov E, Schmitz N, Lenz G, et al
     Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs.
     Br J Haematol. 2024 Oct 28. doi: 10.1111/bjh.19860.
     PubMed     Abstract available
     
     
     
105. FUKUOKA K, Zhao J, Oshima K, Honda M, et al
     Isolated testicular second-relapsed T-lymphoblastic lymphoma after allogeneic stem cell transplantation: Therapeutic implication from sequential molecular genetic analysis.
     Br J Haematol. 2024 Oct 27. doi: 10.1111/bjh.19870.
     PubMed    
     
     
     
106. ALBANO D
     (18)F-FDG PET/CT impact in grade 3B follicular lymphoma.
     Br J Haematol. 2024 Oct 27. doi: 10.1111/bjh.19852.
     PubMed     Abstract available
     
     
     
107. JIANG L, Dreyling M, Hermine O, Mansmann U, et al
     Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.
     Br J Haematol. 2024 Oct 23. doi: 10.1111/bjh.19854.
     PubMed     Abstract available
     
     
     
108. YOSHIMITSU M, Tanaka T, Nakano N, Kato K, et al
     Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma.
     Br J Haematol. 2024 Oct 19. doi: 10.1111/bjh.19835.
     PubMed     Abstract available
     
     
     
109. BUCCHERI V, Moreira FR, Biasoli I, Castro N, et al
     External validation and calibration of the HoLISTIC Consortium's advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in the Brazilian Hodgkin lymphoma registry.
     Br J Haematol. 2024 Oct 17. doi: 10.1111/bjh.19824.
     PubMed     Abstract available
     
     
     
110. LE GALLO M, Rose J, Safa F, Cottin L, et al
     Bone marrow metastasis of rhabdomyosarcoma mimicking high-grade lymphoma in a young man.
     Br J Haematol. 2024 Oct 15. doi: 10.1111/bjh.19795.
     PubMed    
     
     
     
111. CHIRIAC R, Baseggio L
     Monomorphic epitheliotropic intestinal T-cell lymphoma involving the aqueous humour.
     Br J Haematol. 2024 Oct 14. doi: 10.1111/bjh.19806.
     PubMed    
     
     
     
112. BARRACLOUGH A, Lee ST, Villa D, Hapgood G, et al
     The value of semiquantitative PET features and end-of-therapy PET in grade 3B follicular lymphoma.
     Br J Haematol. 2024 Oct 13. doi: 10.1111/bjh.19823.
     PubMed     Abstract available
     
     
     
113. SHERIF M, Schafer H, Scharf S, van Oostendorp V, et al
     EZB-type diffuse large B-cell lymphoma cell lines have superior migration capabilities compared to MCD-type.
     Br J Haematol. 2024 Oct 2. doi: 10.1111/bjh.19778.
     PubMed     Abstract available
     
     
     
114. WU S, Luo Q, Li F, Zhang S, et al
     Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms.
     Br J Haematol. 2024;205:1361-1373.
     PubMed     Abstract available
     
     
     
115. BARONE A, Chiappella A, Casadei B, Bramanti S, et al
     Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study.
     Br J Haematol. 2024;205:1356-1360.
     PubMed     Abstract available
     
     
     September 2024
116. LIU J, Gao F, Zhang T, Wang J, et al
     Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysis.
     Br J Haematol. 2024 Sep 26. doi: 10.1111/bjh.19770.
     PubMed     Abstract available
     
     
     
117. STRATI P, Champion R, Coleman M, Smith SM, et al
     Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.
     Br J Haematol. 2024 Sep 22. doi: 10.1111/bjh.19787.
     PubMed     Abstract available
     
     
     
118. MUNSHI M, Liu X, Kofides A, Tsakmaklis N, et al
     ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells.
     Br J Haematol. 2024 Sep 18. doi: 10.1111/bjh.19756.
     PubMed     Abstract available
     
     
     
119. KURUVILLA J, Rushton C, Villa D, Aslam M, et al
     A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma.
     Br J Haematol. 2024 Sep 12. doi: 10.1111/bjh.19764.
     PubMed     Abstract available
     
     
     
120. NARESH KN
     Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions.
     Br J Haematol. 2024 Sep 10. doi: 10.1111/bjh.19754.
     PubMed     Abstract available
     
     
     
121. FORSGREN E, Ekberg S, Smedby KE, Nylund P, et al
     Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers.
     Br J Haematol. 2024 Sep 3. doi: 10.1111/bjh.19732.
     PubMed     Abstract available
     
     
     
122. SHOUVAL R, Goldman A, Flynn JR, El-Moghraby A, et al
     Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile.
     Br J Haematol. 2024;205:978-989.
     PubMed     Abstract available
     
     
     August 2024
123. PIGNOT PE, Bahri H, Malartre S, Morisset S, et al
     Impact of the total lesion glycolysis (TLG) in predicting response of follicular lymphoma to rituximab.
     Br J Haematol. 2024 Aug 27. doi: 10.1111/bjh.19724.
     PubMed    
     
     
     
124. KUMAR EA, Korfi K, Bewicke-Copley F, Close K, et al
     CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma.
     Br J Haematol. 2024 Aug 26. doi: 10.1111/bjh.19671.
     PubMed     Abstract available
     
     
     
125. WILSON MR, Cwynarski K, Eyre TA, Smith J, et al
     Central nervous system prophylaxis in large B-cell lymphoma: A British Society for Haematology Good Practice Paper.
     Br J Haematol. 2024 Aug 11. doi: 10.1111/bjh.19686.
     PubMed     Abstract available
     
     
     
126. HERSHENFELD SA, Tobin JWD, Shelton V, Calvente L, et al
     Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy.
     Br J Haematol. 2024 Aug 7. doi: 10.1111/bjh.19698.
     PubMed     Abstract available
     
     
     
127. YI JH, Kim SJ, Yang DH, Do YR, et al
     Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma.
     Br J Haematol. 2024 Aug 5. doi: 10.1111/bjh.19659.
     PubMed     Abstract available
     
     
     
128. AARNIVALA H, Giertz M, Michelsen SW, Bjorklund C, et al
     Radiological follow-up of osteonecrosis lesions in children and adolescents with Hodgkin lymphoma.
     Br J Haematol. 2024 Aug 3. doi: 10.1111/bjh.19687.
     PubMed     Abstract available
     
     
     
129. CORAZZELLI G, Cuccaro A, Morelli E, Arcamone M, et al
     Long-term efficacy and safety of dose-dense and dose-intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15-year follow-up of the ABVD(DD-DI) phase II study.
     Br J Haematol. 2024 Aug 1. doi: 10.1111/bjh.19646.
     PubMed     Abstract available
     
     
     
130. MUHSEN IN, Heslop HE
     Time to optimize vaccination strategies in blood cancer patients.
     Br J Haematol. 2024;205:406-408.
     PubMed     Abstract available
     
     
     July 2024
131. SPRIANO F, Tarantelli C, Cascione L, Gaudio E, et al
     Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents.
     Br J Haematol. 2024 Jul 30. doi: 10.1111/bjh.19658.
     PubMed     Abstract available
     
     
     
132. BALZAROTTI M, Bagnoli F
     Rolling the DICEP on lymphoma salvage treatments? Choose wisely.
     Br J Haematol. 2024 Jul 27. doi: 10.1111/bjh.19655.
     PubMed     Abstract available
     
     
     
133. KAMIJO K, Shimomura Y, Kim SW, Ohigashi H, et al
     Reduced-intensity conditioning with fludarabine/busulfan versus fludarabine/low-dose melphalan in patients with non-Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation.
     Br J Haematol. 2024 Jul 24. doi: 10.1111/bjh.19651.
     PubMed     Abstract available
     
     
     
134. GALLAMINI A, Filippi A, Camus V, Vassilakopoulos TP, et al
     Toward a paradigm shift in prognostication and treatment of early-stage Hodgkin lymphoma.
     Br J Haematol. 2024 Jul 22. doi: 10.1111/bjh.19657.
     PubMed     Abstract available
     
     
     
135. PINTO A, Caltagirone M, Battista M, Gazzoli GC, et al
     Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma.
     Br J Haematol. 2024 Jul 22. doi: 10.1111/bjh.19661.
     PubMed     Abstract available
     
     
     
136. CARLO-STELLA C
     Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss.
     Br J Haematol. 2024;205:17-19.
     PubMed     Abstract available
     
     
     
137. GRIGG S, Minson A, Prins E, Dickinson MJ, et al
     Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high.
     Br J Haematol. 2024;205:122-126.
     PubMed     Abstract available
     
     
     
138. CIVALLERO M, Schroers-Martin JG, Horwitz S, Manni M, et al
     Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project.
     Br J Haematol. 2024;205:166-174.
     PubMed     Abstract available
     
     
     June 2024
139. CAVALLO F, Clerico M, Lucchini E, Castiglione A, et al
     Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi.
     Br J Haematol. 2024 Jun 28. doi: 10.1111/bjh.19617.
     PubMed     Abstract available
     
     
     
140. PRIOR D, Schmitt AD, Louissaint A, Mata DA, et al
     Large B-cell lymphoma with mystery rearrangement: Applying Hi-C to the detection of clinically relevant structural abnormalities.
     Br J Haematol. 2024 Jun 25. doi: 10.1111/bjh.19611.
     PubMed    
     
     
     
141. LIM YJ, Ward V, Brown A, Phillips E, et al
     Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
     Br J Haematol. 2024 Jun 13. doi: 10.1111/bjh.19562.
     PubMed     Abstract available
     
     
     
142. ROSSETTI S, Juul SJ, Eriksson F, Warming PE, et al
     Long-term cause-specific mortality in adolescent and young adult Hodgkin lymphoma patients treated with contemporary regimens-A nationwide Danish cohort study.
     Br J Haematol. 2024 Jun 12. doi: 10.1111/bjh.19586.
     PubMed     Abstract available
     
     
     
143. SCIARRA R, Merli M, Cristinelli C, Lucioni M, et al
     Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection.
     Br J Haematol. 2024;204:2242-2253.
     PubMed     Abstract available
     
     
     May 2024
144. SHORTT J, Opat S
     Large cell lymphoma through a liquid lens.
     Br J Haematol. 2024 May 30. doi: 10.1111/bjh.19502.
     PubMed     Abstract available
     
     
     
145. ALCOCEBA M, Stewart JP, Garcia-Alvarez M, Diaz LG, et al
     Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease.
     Br J Haematol. 2024 May 29. doi: 10.1111/bjh.19458.
     PubMed     Abstract available
     
     
     
146. STEWART DA, Kuruvilla J, Lee D, Dudebout JJ, et al
     Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide,
     Br J Haematol. 2024 May 27. doi: 10.1111/bjh.19555.
     PubMed     Abstract available
     
     
     
147. OTHMAN T, Baird JH, Pak S, Mei M, et al
     Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.
     Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19521.
     PubMed    
     
     
     
148. EPPERLA N, Hashmi H, Ahn KW, Allbee-Johnson M, et al
     Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis.
     Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19569.
     PubMed    
     
     
     
149. RUPAKUMAR T, Sankar A, Vijayasekharan K, Varikkattu Rajendran P, et al
     Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia/lymphoma: Experience from a tertiary care centre in South India.
     Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19559.
     PubMed     Abstract available
     
     
     
150. HOFER KD, Wolfensberger N, Bachofner A, Schneidawind C, et al
     B-cell maturation antigen-directed bispecific antibodies in plasmablastic lymphoma.
     Br J Haematol. 2024 May 23. doi: 10.1111/bjh.19571.
     PubMed    
     
     
     
151. COELHO J, Roush SM, Xu AM, Puranam K, et al
     HIV and prior exposure to antiretroviral therapy alter tumour composition and tumour: T-cell associations in diffuse large B-cell lymphoma.
     Br J Haematol. 2024 May 20. doi: 10.1111/bjh.19531.
     PubMed     Abstract available
     
     
     
152. BROCKELMANN PJ
     Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma.
     Br J Haematol. 2024 May 16. doi: 10.1111/bjh.19534.
     PubMed     Abstract available
     
     
     
153. KUCZMARSKI TM, Lynch RC
     Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma.
     Br J Haematol. 2024 May 2. doi: 10.1111/bjh.19478.
     PubMed     Abstract available
     
     
     
154. SOUMERAI JD, Diefenbach CS, Jagadeesh D, Asch A, et al
     Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
     Br J Haematol. 2024;204:1762-1770.
     PubMed     Abstract available
     
     
     
155. BRILLEMBOURG H, Martinez-Cibrian N, Bachiller M, Alserawan L, et al
     The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
     Br J Haematol. 2024;204:1649-1659.
     PubMed     Abstract available
     
     
     
156. FARDELLA E, Zanirato G, Magni M, Caldarelli N, et al
     Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas.
     Br J Haematol. 2024;204:1752-1756.
     PubMed     Abstract available
     
     
     April 2024
157. VANDTVED JH, Ovlisen AK, Baech J, Weinrich UM, et al
     Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study.
     Br J Haematol. 2024 Apr 29. doi: 10.1111/bjh.19475.
     PubMed     Abstract available
     
     
     
158. HUO W, Gao L, Song K, Huang J, et al
     Allogeneic haematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicentre analysis in China.
     Br J Haematol. 2024 Apr 25. doi: 10.1111/bjh.19481.
     PubMed     Abstract available
     
     
     
159. LEWIS CS, Joy G, Jensen P, Barraclough A, et al
     Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study.
     Br J Haematol. 2024 Apr 17. doi: 10.1111/bjh.19470.
     PubMed     Abstract available
     
     
     
160. CAO XY, Zhang JP, Lu Y, Zhao YL, et al
     A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen r
     Br J Haematol. 2024 Apr 13. doi: 10.1111/bjh.19445.
     PubMed     Abstract available
     
     
     
161. GANAPATHI KA, Nicolae A, Egan C, Geng H, et al
     Peripheral T-cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK-negative.
     Br J Haematol. 2024 Apr 12. doi: 10.1111/bjh.19442.
     PubMed     Abstract available
     
     
     
162. KUHNL A, Roddie C, Kirkwood AA, Chaganti S, et al
     Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.
     Br J Haematol. 2024 Apr 9. doi: 10.1111/bjh.19453.
     PubMed     Abstract available
     
     
     
163. MARTYNCHYK A, Hawkes EA
     Learnings from phosphatidylinositol 3-kinase inhibitors in lymphoma-Moving to a model where less can be more.
     Br J Haematol. 2024 Apr 6. doi: 10.1111/bjh.19456.
     PubMed     Abstract available
     
     
     
164. ATALLAH-YUNES SA, Habermann TM, Khurana A
     Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation.
     Br J Haematol. 2024 Apr 5. doi: 10.1111/bjh.19425.
     PubMed     Abstract available
     
     
     
165. MILROD CJ, Kim KW, Raker C, Ollila TA, et al
     Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: A systematic review and meta-analysis.
     Br J Haematol. 2024 Apr 4. doi: 10.1111/bjh.19449.
     PubMed     Abstract available
     
     
     
166. BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
     Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
     Br J Haematol. 2024;204:1367-1374.
     PubMed     Abstract available
     
     
     
167. MOULIN C, Beaupain B, Suarez F, Bertrand Y, et al
     CXCR4 WHIM syndrome is a cancer predisposition condition for virus-induced malignancies.
     Br J Haematol. 2024;204:1383-1392.
     PubMed     Abstract available
     
     
     March 2024
168. MERLI M, Costantini A, Tafuri S, Bavaro DF, et al
     Management of vaccinations in patients with non-Hodgkin lymphoma.
     Br J Haematol. 2024 Mar 26. doi: 10.1111/bjh.19422.
     PubMed     Abstract available
     
     
     
169. MANOS K, Churilov L, Grigg A, Di Ciaccio P, et al
     Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study.
     Br J Haematol. 2024 Mar 14. doi: 10.1111/bjh.19407.
     PubMed     Abstract available
     
     
     
170. BAPTISTA P, Aguiar E, Fonseca E, Pinto R, et al
     Intravascular large B-cell lymphoma presenting with haemophagocytic syndrome.
     Br J Haematol. 2024 Mar 12. doi: 10.1111/bjh.19350.
     PubMed    
     
     
     
171. LI X, Gao F, Meng X, Zhang X, et al
     Epidemiological features and prognosis for primary gastrointestinal follicular lymphoma.
     Br J Haematol. 2024 Mar 6. doi: 10.1111/bjh.19393.
     PubMed     Abstract available
     
     
     
172. NGUYEN PC, Nguyen T, Wilson C, Tiong IS, et al
     Evaluation of T-cell clonality by anti-TRBC1 antibody-based flow cytometry and correlation with T-cell receptor sequencing.
     Br J Haematol. 2024;204:910-920.
     PubMed     Abstract available
     
     
     
173. AL-MASHHADI AL, Jakobsen LH, Brown P, Gang AO, et al
     Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas.
     Br J Haematol. 2024;204:839-848.
     PubMed     Abstract available
     
     
     February 2024
174. BISHTON MJ, Crooks CJ, Card TR, West J, et al
     Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma.
     Br J Haematol. 2024 Feb 29. doi: 10.1111/bjh.19371.
     PubMed     Abstract available
     
     
     
175. YE P, Cheng Y, Lian J, Tong H, et al
     Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study.
     Br J Haematol. 2024 Feb 23. doi: 10.1111/bjh.19367.
     PubMed     Abstract available
     
     
     
176. STEPANISHYNA Y, Manni M, Civallero M, Shokun N, et al
     Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021.
     Br J Haematol. 2024 Feb 23. doi: 10.1111/bjh.19352.
     PubMed     Abstract available
     
     
     
177. FLORA DR, Parsons SK, Liu N, Yu KS, et al
     Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey.
     Br J Haematol. 2024 Feb 7. doi: 10.1111/bjh.19307.
     PubMed     Abstract available
     
     
     
178. VOGELSBERG A, Harland L, Borgmann V, Otto F, et al
     Clonal haematopoiesis: A common progenitor for cytotoxic peripheral T-cell lymphoma and angioimmunoblastic T-cell lymphoma.
     Br J Haematol. 2024 Feb 7. doi: 10.1111/bjh.19335.
     PubMed     Abstract available
     
     
     
179. BEDNARSKA K, Chowdhury R, Tobin JWD, Swain F, et al
     Epstein-Barr virus-associated lymphomas decoded.
     Br J Haematol. 2024;204:415-433.
     PubMed     Abstract available
     
     
     
180. WANG Z, Fan Z, Wu Z, Xuan L, et al
     PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
     Br J Haematol. 2024;204:628-637.
     PubMed     Abstract available
     
     
     
181. KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
     Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
     Br J Haematol. 2024;204:561-565.
     PubMed     Abstract available
     
     
     
182. PELLICCIA S, Rogges E, Cardoni A, Lopez G, et al
     The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features.
     Br J Haematol. 2024;204:534-547.
     PubMed     Abstract available
     
     
     January 2024
183. LUEDERSEN J, Stadt UZ, Richter J, Oschlies I, et al
     Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study group.
     Br J Haematol. 2024 Jan 26. doi: 10.1111/bjh.19308.
     PubMed     Abstract available
     
     
     
184. YANG P, Cai M, Cao Y, Fan S, et al
     Up-front autologous stem cell transplant in peripheral T-cell lymphoma patients achieving complete response after first-line treatment: A multicentre real-world analysis.
     Br J Haematol. 2024 Jan 25. doi: 10.1111/bjh.19317.
     PubMed     Abstract available
     
     
     
185. ABEYAKOON C, Gregory GP
     New standards of care for treatment of diffuse large B-cell lymphoma.
     Br J Haematol. 2024 Jan 22. doi: 10.1111/bjh.19295.
     PubMed     Abstract available
     
     
     
186. FOX CP, Chaganti S, McIlroy G, Barrington SF, et al
     The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.
     Br J Haematol. 2024 Jan 21. doi: 10.1111/bjh.19273.
     PubMed    
     
     
     
187. LIAPIS K, Misidou C, Spanoudakis E, Kotsianidis I, et al
     Concurrent visceral leishmaniasis and diffuse large B-cell lymphoma of the bone marrow.
     Br J Haematol. 2024 Jan 7. doi: 10.1111/bjh.19283.
     PubMed    
     
     
     
188. WALEWSKA R, Eyre TA, Barrington S, Brady J, et al
     Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline.
     Br J Haematol. 2024;204:86-107.
     PubMed    
     
     
     
189. VISCO C
     Letting the mantle out of the bag.
     Br J Haematol. 2024;204:11-13.
     PubMed     Abstract available
     
     
     
190. KHWAJA J, Vos JMI, Pluimers TE, Japzon N, et al
     Clinical and clonal characteristics of monoclonal immunoglobulin M-associated type I cryoglobulinaemia.
     Br J Haematol. 2024;204:177-185.
     PubMed     Abstract available
     
     
     
191. DODERO A, Bramanti S, Di Trani M, Pennisi M, et al
     Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas.
     Br J Haematol. 2024;204:151-159.
     PubMed     Abstract available
     
     
     December 2023
192. BAECH J, Husby S, Trab T, Kragholm K, et al
     Cardiovascular diseases after high-dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population-based study.
     Br J Haematol. 2023 Dec 28. doi: 10.1111/bjh.19272.
     PubMed     Abstract available
     
     
     
193. MOTOMURA Y, Yoshifuji K, Tachibana T, Takase H, et al
     Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma.
     Br J Haematol. 2023 Dec 22. doi: 10.1111/bjh.19266.
     PubMed     Abstract available
     
     
     
194. TOTARO A, Calafiore AM, Sacra C, Magnano D, et al
     Huge right atrial mass in mantle cell lymphoma.
     Br J Haematol. 2023 Dec 21. doi: 10.1111/bjh.19258.
     PubMed    
     
     
     
195. JIN X, Zhou W, Jiang H, Chen Z, et al
     A case of a large number of Reed-Sternberg cells in pleural fluid following treatment of classical Hodgkin lymphoma.
     Br J Haematol. 2023 Dec 20. doi: 10.1111/bjh.19260.
     PubMed    
     
     
     
196. MASRONI MSB, Leong SM, Cheng H, Lim GS, et al
     miR-101-5p modulation of CD47 in diffuse large B-cell lymphoma: Implications for anti-CD47 immunotherapy and prognostication.
     Br J Haematol. 2023 Dec 12. doi: 10.1111/bjh.19264.
     PubMed    
     
     
     
197. FLOSPERGHER E, Marino F, Calimeri T, Cangi MG, et al
     Primary central nervous system marginal zone lymphoma.
     Br J Haematol. 2023 Dec 6. doi: 10.1111/bjh.19238.
     PubMed     Abstract available
     
     
     
198. WU JF, Abid H, Szabo A, Abid MB, et al
     Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
     Br J Haematol. 2023;203:e117-e120.
     PubMed    
     
     
     November 2023
199. SARTORI G, Tarantelli C, Spriano F, Gaudio E, et al
     The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
     Br J Haematol. 2023 Nov 27. doi: 10.1111/bjh.19218.
     PubMed     Abstract available
     
     
     
200. WATANABE T, Tobinai K, Wakabayashi M, Maruyama D, et al
     R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
     Br J Haematol. 2023 Nov 23. doi: 10.1111/bjh.19213.
     PubMed     Abstract available
     
     
     
201. HEINI AD, Bacher U, Pabst T
     Identification of novel targets for immunotherapies in subsets of patients with diffuse large B-cell lymphoma (DLBCL).
     Br J Haematol. 2023 Nov 14. doi: 10.1111/bjh.19195.
     PubMed     Abstract available
     
     
     
202. CARACCIOLO D, Polera N, Belmonte B, Conforti F, et al
     UMG1/CD3epsilon-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
     Br J Haematol. 2023 Nov 14. doi: 10.1111/bjh.19183.
     PubMed     Abstract available
     
     
     
203. PEDERSEN MA, Gormsen LC, Jakobsen LH, Eyre TA, et al
     The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study.
     Br J Haematol. 2023 Nov 13. doi: 10.1111/bjh.19194.
     PubMed     Abstract available
     
     
     
204. GALLI E, Bellesi S, Pansini I, Di Cesare G, et al
     The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity.
     Br J Haematol. 2023;203:564-570.
     PubMed     Abstract available
     
     
     October 2023
205. MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
     The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
     Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
     PubMed     Abstract available
     
     
     
206. STUVER R, Noy A, Vardhana SA, Zelenetz AD, et al
     Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.
     Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19178.
     PubMed    
     
     
     
207. MINSON A, Hamad N, Di Ciaccio P, Talaulikar D, et al
     Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.
     Br J Haematol. 2023 Oct 30. doi: 10.1111/bjh.19179.
     PubMed     Abstract available
     
     
     
208. GONG IY, Prica A, Ante Z, Calzavara A, et al
     Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, Canada.
     Br J Haematol. 2023 Oct 27. doi: 10.1111/bjh.19166.
     PubMed     Abstract available
     
     
     
209. RAMSOWER CA, Rosenthal A, Robetorye RS, Mwangi R, et al
     Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
     Br J Haematol. 2023 Oct 25. doi: 10.1111/bjh.19153.
     PubMed     Abstract available
     
     
     
210. EYRE TA, Bishton MJ, McCulloch R, O'Reilly M, et al
     Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline.
     Br J Haematol. 2023 Oct 25. doi: 10.1111/bjh.19131.
     PubMed    
     
     
     
211. CALABRETTA E, di Trani M, Corrado F, Sollini M, et al
     Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.
     Br J Haematol. 2023 Oct 18. doi: 10.1111/bjh.19162.
     PubMed     Abstract available
     
     
     
212. BOYLE S, Roddie C, O'Reilly M, Menne T, et al
     Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.
     Br J Haematol. 2023 Oct 17. doi: 10.1111/bjh.19157.
     PubMed     Abstract available
     
     
     
213. KYVSGAARD ER, Riley C, Clausen MR, Harslof M, et al
     Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy.
     Br J Haematol. 2023 Oct 13. doi: 10.1111/bjh.19156.
     PubMed    
     
     
     
214. MAMLOUK O, Strati P, Feng L, Sun R, et al
     Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function.
     Br J Haematol. 2023 Oct 11. doi: 10.1111/bjh.19152.
     PubMed    
     
     
     
215. CONTARINI G, Carraro E, Lovisa F, Martire G, et al
     Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large-cell lymphoma treated with brentuximab vedotin: A case series.
     Br J Haematol. 2023 Oct 11. doi: 10.1111/bjh.19151.
     PubMed    
     
     
     
216. LIU H, He Z, Gui R, Guo J, et al
     Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients.
     Br J Haematol. 2023 Oct 6. doi: 10.1111/bjh.19140.
     PubMed     Abstract available
     
     
     
217. GAO J, Dahiya S, Patel SA
     Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.
     Br J Haematol. 2023;203:161-168.
     PubMed     Abstract available
     
     
     September 2023
218. LEWIS KL, Cheah CY
     Chimeric antigen receptor T-cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect.
     Br J Haematol. 2023 Sep 24. doi: 10.1111/bjh.19095.
     PubMed    
     
     
     
219. HAYASHI K, Koyama D, Sato Y, Fukatsu M, et al
     Lymphoplasmacytic lymphoma presenting cold agglutinin syndrome: Clonal expansion of KMT2D and IGHV4-34 mutations after COVID-19.
     Br J Haematol. 2023 Sep 11. doi: 10.1111/bjh.19106.
     PubMed    
     
     
     
220. XIONG J, Zhao WL
     A novel SLC1A1-RIC1 fusion sensitive to asparaginase-based therapy in natural killer/T-cell lymphoma.
     Br J Haematol. 2023 Sep 1. doi: 10.1111/bjh.19066.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.